Table 1.
Characteristics of basket trials for symptomatic agents in neurodegenerative disorders
| Drug | Number of trials | Goal of treatment | NDDs included |
|---|---|---|---|
| Alprazolam | 1 | Reduced anxiety | HD, AD |
| Ampreloxetine | 1 | Control of orthostatic hypotension | PD, MSA |
| Apomorphine | 1 | Pain control | CBD, PSP |
| Armodafinil | 1 | Improved attention, cognitive enhancement | PD, DLB |
| AVP-786 | 1 | Reduced disinhibition | DLB, AD, PSP, HD, FTLD |
| AVP-923 | 2 | Control of pseudobulbar affect | AD, PD, HD, ALS |
| Botulinum toxin | 1 | Reduction of rigidity | AD, FTLD |
| Cannabis | 2 | Improved sense of well-being, improved quality of life; reduction of pain, nausea, vomiting | PD, CTE, ALS |
| Carbidopa | 1 | Improved motor function | MSA, PD |
| Droxidopa | 7 | Improved motor and non-motor symptoms, increased blood pressure | PD, MSA, PSP |
| Entacapone | 1 | Improved motor function | MSA, PD |
| Incobotulinum Toxin A | 2 | Reduced salivary volume | PD, ALS, MSA, PSP |
| Intepirdine (RVT-101) | 1 | Improved gait | DLB, AD, PD |
| Lithium | 1 | Improved quality of life, reduced depression | CBD, PSP |
| LY31544207 | 1 | Cognitive enhancement | DLB, PD |
| Memantine | 2 | Cognitive enhancement | PD, DLB, FTLD, ALS |
| Midodrine | 4 | Control of orthostatic hypotension | MSA, PD |
| MP-101 | 1 | Reduction of dementia-related psychosis | AD, FTLD, PD, DLB |
| Nebivolol | 1 | Control of hypotension | MSA, PD |
| Nelotanserin | 3 | Reduced REM sleep behavior disorders, reduced visual hallucinations | PD, DLB |
| NYX-458 | 1 | Cognitive enhancement | PD, DLB |
| Pimavanserin | 2 | Reduction of dementia-related psychosis with delusions and hallucinations | AD, PD, DLB, FTLD |
| Ramalteon | 1 | Improved sleep efficiency | HD, DLB, PD |
| Rimabotulinum toxin B | 1 | Reduced sialorrhea | PD, ALS |
| TD-9855 | 1 | Reduced orthostatic hypotension | MSA, PD |